These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33962762)

  • 1. Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
    Groenendaal-van de Meent D; Kerbusch V; Barroso-Fernandez B; den Adel M; van Dijk J; Golor G; Schaddelee M
    Clin Ther; 2021 Jun; 43(6):1079-1091. PubMed ID: 33962762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.
    Shibata T; Nomura Y; Takada A; Aoki S; Katashima M; Murakami H
    J Clin Pharm Ther; 2018 Oct; 43(5):633-639. PubMed ID: 29981285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent.
    Pai SM; Yamada H
    Clin Pharmacol Drug Dev; 2024 Jan; 13(1):111-116. PubMed ID: 37975611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults.
    Paulson SK; Martinez J; Sawant R; Burke SK; Chavan A
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):475-485. PubMed ID: 35172045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.
    Shibata T; Nomura Y; Takada A; Ueno M; Katashima M; Yazawa R; Furihata K
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):304-313. PubMed ID: 29966038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin.
    Kays MB; Overholser BR; Mueller BA; Moe SM; Sowinski KM
    Am J Kidney Dis; 2003 Dec; 42(6):1253-9. PubMed ID: 14655198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.
    Groenendaal-van de Meent D; den Adel M; van Dijk J; Barroso-Fernandez B; El Galta R; Golor G; Schaddelee M
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):685-692. PubMed ID: 29752643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Groenendaal-van de Meent D; Kerbusch V; Kaspera R; Barroso-Fernandez B; Galletti P; Klein GK; den Adel M
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):141-153. PubMed ID: 33165773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease.
    Rekić D; Kerbusch-Herben V; Någård M; Chou J; Huang J; Bradley C; Åstrand M; Tannenbaum S; Hamrén B
    Clin Pharmacokinet; 2021 Jun; 60(6):759-773. PubMed ID: 33486718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of phosphate binders on supplemental iron absorption in healthy subjects.
    Pruchnicki MC; Coyle JD; Hoshaw-Woodard S; Bay WH
    J Clin Pharmacol; 2002 Oct; 42(10):1171-6. PubMed ID: 12362933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study.
    Groenendaal-van de Meent D; den Adel M; Rijnders S; Krebs-Brown A; Kerbusch V; Golor G; Schaddelee M
    Clin Ther; 2016 Apr; 38(4):918-28. PubMed ID: 26947173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies.
    Groenendaal-van de Meent D; den Adel M; Kerbusch V; van Dijk J; Shibata T; Kato K; Schaddelee M
    Clin Pharmacol Drug Dev; 2022 Apr; 11(4):486-501. PubMed ID: 35182045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
    J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D.
    Yusuf AA; Weinhandl ED; St Peter WL
    Am J Kidney Dis; 2014 Jul; 64(1):95-103. PubMed ID: 24387795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.
    Covic A; Passlick-Deetjen J; Kroczak M; Büschges-Seraphin B; Ghenu A; Ponce P; Marzell B; de Francisco AL
    Nephrol Dial Transplant; 2013 Sep; 28(9):2383-92. PubMed ID: 23787550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.